Clinical trial
A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Therapeutic Confirmatory Study and Open-Label Extension Study to Evaluate the Efficacy and Safety of DWP16001 Add-on to Metformin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
NCT05505994 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Therapeutic Confirmatory Study and Open-Label Extension Study to Evaluate the Efficacy and Safety of DWP16001 Add-on to Metformin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 28, 2022
- Completion date
- September 30, 2024
- Enrollment
- 340 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus, diabetes mellitus, type 2, endocrine system diseases, glucose metabolism disorders, metabolic disease